CORDIS · 896183 · H2020
MEGAKINE Megakines - novel tools for structural insight into receptor:chemokine complexes
Coordinator: LUXEMBOURG INSTITUTE OF HEALTH (LU)
Chemokines are small, secreted cytokines that activate membrane receptors belonging to the G protein-coupled receptor (GPCR) superfamily. The chemokine-receptor interactions control crucial physiological processes, but are also implicated in many pathologies, including atherosclerosis, inflammatory diseases, HIV infection or cancer, and hold a great potential for therapeutic intervention. Yet, although GPCRs are the target of about one third of currently marketed drugs, only three of them act on chemokine receptors, essentially due to poor structural understanding of the intricate interaction…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €178k awarded to the consortium. The project runs over approximately 2 years from 2021-09-01 to 2023-08-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from LU
see all →- HEDGE-IoT — Holistic Approach towards Empowerment of the DiGitalization of the Energy Ecosystem through adoption of IoT solutions101136216 · HORIZON · €18.0M
- DESIDERATA — Integrated Pathways: Advancing Safe and Sustainable by Design Material Innovation through Collaborative Wisdom101178011 · HORIZON · €10.7M
- TrustChain — Fostering a Human-Centered, Trustworthy and Sustainable Internet101093274 · HORIZON · €10.6M
- HealthyW8 — Empowering healthy lifestyle behaviour through personalised intervention portfolios to prevent and control obesity during vulnerable stages of life101080645 · HORIZON · €10.0M
- PATH — Patient AI Treatment Hub101253520 · HORIZON · €8.9M
- ALCEMIST — Atypical Liquid Crystal Elastomers: from Materials Innovation to Scalable processing and Transformative applications101167171 · HORIZON · €8.5M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the MSCA-IF funding scheme.
- What is the EU contribution?
- The European Commission contributes €178k toward a total project budget of €178k.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-MSCA-IF-2019.
- Who coordinates the project?
- The project is coordinated by LUXEMBOURG INSTITUTE OF HEALTH (LU).
- What is the project timeline?
- The project runs from 2021-09-01 to 2023-08-31 — approximately 2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 896183.